Prevention of progression of Parkinson's disease with antioxidative therapy
- 1 January 1988
- journal article
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 12 (2-3) , 165-172
- https://doi.org/10.1016/0278-5846(88)90034-6
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- LIPID PEROXIDATION AS CAUSE OF NIGRAL CELL DEATH IN PARKINSON'S DISEASEThe Lancet, 1986
- Antioxidants fail to inhibit depletion of striatal dopamine by MPTPNeurology, 1986
- Permanent human parkinsonism due to 1‐methy 1–4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)Neurology, 1985
- Increased life expectancy resulting from addition of l-deprenyl to Madopar® treatment in Parkinson's disease: A longterm studyJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1985
- The Clinical Syndrome of Striatal Dopamine DeficiencyNew England Journal of Medicine, 1985
- Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeysEuropean Journal of Pharmacology, 1984
- Etiology of Parkinson’s Disease: A Research StrategyCanadian Journal of Neurological Sciences, 1984
- Chronic parkinsonism secondary to intravenous injection of meperidine analoguesPsychiatry Research, 1979
- Brain Peroxidase and Catalase in Parkinson DiseaseArchives of Neurology, 1975
- DEPOSITS OF FLUORESCENT ACID-FAST PRODUCTS IN THE NERVOUS SYSTEM AND SKELETAL MUSCLES OF ADULT RATS WITH CHRONIC VITAMIN-E DEFICIENCYJournal of Neurology, Neurosurgery & Psychiatry, 1953